AR065504A1 - COMBINED THERAPY FOR THE TREATMENT OF CHRONIC HEPATITIS B. USE. - Google Patents

COMBINED THERAPY FOR THE TREATMENT OF CHRONIC HEPATITIS B. USE.

Info

Publication number
AR065504A1
AR065504A1 ARP080100816A ARP080100816A AR065504A1 AR 065504 A1 AR065504 A1 AR 065504A1 AR P080100816 A ARP080100816 A AR P080100816A AR P080100816 A ARP080100816 A AR P080100816A AR 065504 A1 AR065504 A1 AR 065504A1
Authority
AR
Argentina
Prior art keywords
antiviral
treatment
association
drugs
hbv
Prior art date
Application number
ARP080100816A
Other languages
Spanish (es)
Inventor
Rubido Julio Cesar Aguilar
Arias Eduardo Penton
Gonzalez Verena Lucila Muzio
Laurent Guillot
Gomez Raimundo Ubieta
Blanco Sonia Gonzalez
Martinez Luis Saturnino Herrera
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR065504A1 publication Critical patent/AR065504A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Uso de un inmunopreparado de naturaleza proteoliposomal que comprende a la proteína ôSö del virus de la hepatitis B (VHB) obtenida mediante inmunoafinidad para la preparacion de una composicion farmacéutica para el tratamiento de pacientes conhepatitis B cronica mediante un método que consiste en la administracion de dicho inmunopreparado en asociacion con una cantidad efectiva de un antiviral con actividad inhibidora de la replicacion del VHB, caracterizada en que el tratamientoantiviral se realiza en un tiempo igual o inferior a los 6 meses. La administracion de ambos fármacos en asociacion resulta en niveles de eficacia superiores a los obtenidos con los tratamientos convencionales, en cuanto a respuesta terapéuticaclínicamente significativa, caracterizada por una disminucion de la carga viral por debajo de 10.000 copias por mL de suero, normalizacion de las transaminasas y mejoría de los índices de dano histologico. Producto del tiempo en que se administranambos fármacos en asociacion, se elimina la aparicion de mutantes de escape a los antivirales. Reivindicacion 11: Un método para incrementar los niveles de anticuerpos en pacientes de HBC mediante la administracion de un inmunopreparadoproteoliposomal que comprende la proteína ôSö de la envoltura del VHB, obtenida mediante inmunoafinidad, en asociacion con un antiviral perteneciente al grupo de inhibidores de la polimerasa viral utilizados para el tratamiento de la HBC en unperíodo igual o inferior a los 6 meses de tratamiento antiviral.Use of an immunopreparate of proteoliposomal nature comprising the ôSö protein of hepatitis B virus (HBV) obtained by immunoaffinity for the preparation of a pharmaceutical composition for the treatment of patients with chronic hepatitis B by a method consisting of the administration of said immunoprepaired in association with an effective amount of an antiviral with HBV replication inhibitory activity, characterized in that the antiviral treatment is performed in a time equal to or less than 6 months. The administration of both drugs in association results in higher levels of efficacy than those obtained with conventional treatments, in terms of the clinically significant therapeutic response, characterized by a decrease in viral load below 10,000 copies per mL of serum, normalization of transaminases and improvement of histological damage rates. As a result of the time when both drugs are administered in association, the occurrence of escape mutants to antiviral drugs is eliminated. Claim 11: A method for increasing antibody levels in HBC patients by administering an immunopreparate proteoliposomal comprising the ôSö protein of the HBV envelope, obtained by immunoaffinity, in association with an antiviral belonging to the group of viral polymerase inhibitors used for the treatment of HBC in a period equal to or less than 6 months of antiviral treatment.

ARP080100816A 2007-02-28 2008-02-27 COMBINED THERAPY FOR THE TREATMENT OF CHRONIC HEPATITIS B. USE. AR065504A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070050 2007-02-28

Publications (1)

Publication Number Publication Date
AR065504A1 true AR065504A1 (en) 2009-06-10

Family

ID=39564658

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100816A AR065504A1 (en) 2007-02-28 2008-02-27 COMBINED THERAPY FOR THE TREATMENT OF CHRONIC HEPATITIS B. USE.

Country Status (2)

Country Link
AR (1) AR065504A1 (en)
WO (1) WO2008104133A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23740A1 (en) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech METHOD OF OBTAINING A FORMATION OF ANTIGENS FROM THE HEPATITIS B VIRUS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012544A3 (en) * 1999-01-12 2002-01-16 Smithkline Beecham Biologicals S.A. Pharmaceutical packing
CN1364644A (en) * 2002-02-05 2002-08-21 北京多米诺医药研究所 Immuno liposome therapeutic hepatitis B vaccine and its preparing method

Also Published As

Publication number Publication date
WO2008104133A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
Perrillo Treatment of chronic hepatitis B with interferon: experience in western countries
CN1094642A (en) Therapeutic combination
WO2016173486A1 (en) Use of trimethazine in preparation of drugs for preventing and treating liver diseases
AR065731A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2- [6- (3-AMINO-PIPENIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PRIMIDIN-1-IL METHYL] -4-FLUORO -BENZONITRILE. USE. TREATMENT METHOD, WEEKLY ADMINISTRATION OF DIPEPTIDILPEPTIDASA INHIBITORS.
Yuen et al. RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients
KR20050044587A (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
RU2012136824A (en) METHODS FOR TREATING HEPATITIS C VIRAL INFECTION
WO2012145575A4 (en) Therapy for leukemia
Lawitz et al. All‐oral therapy with nucleotide inhibitors sofosbuvir and GS‐0938 for 14 days in treatment‐naive genotype 1 hepatitis C (NUCLEAR)
MX2010013522A (en) Telaprevir dosing regimen.
Chang et al. Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model
RU2008151516A (en) METHOD FOR INCREASING THE BIOLOGICAL ACTIVITY OF PURIFIED HSPE7 PROTEIN
AR065504A1 (en) COMBINED THERAPY FOR THE TREATMENT OF CHRONIC HEPATITIS B. USE.
Kumar Novel coronavirus (COVID-19) outbreak: Hope and search for effective therapeutic agent
Cusack et al. Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11‐year‐old girl
RU2013120345A (en) NEW METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
JP2019535830A5 (en)
Sho et al. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C
CN114796233A (en) Application of asiatic acid in preparing medicine for treating hepatitis B
US9084758B2 (en) Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof
US9345733B1 (en) Supplement composition for supporting telomere maintenance and protection and method of use
Hosseinnezhad et al. Acute renal failure, thrombocytopenia, and elevated liver enzymes after concurrent abuse of alcohol and cocaine
CN107308121A (en) The therapeutic agent of liver regeneration
Bao-En Ademetionine 1, 4-Butanedisulphonate vs Traditional Chinese medicine for the treatment of acute viral hepatitis with hepatocellular jaundice
AR062894A1 (en) FORMULATIONS FOR THERAPEUTIC ESTIMULATION HORMONE THERAPEUTIC ADMINISTRATION (THS)

Legal Events

Date Code Title Description
FB Suspension of granting procedure